Status:
UNKNOWN
Use of mOPV1 in Routine Immunization in Pakistan.
Lead Sponsor:
Aga Khan University
Collaborating Sponsors:
World Health Organization
Conditions:
Oral Polio Vaccine
Eligibility:
All Genders
Up to 5 years
Phase:
NA
Brief Summary
Pakistan has uninterrupted circulation of polioviruses and this may threaten the entire global community. Bivalent OPV (bOPV), which protects against types 1 and 3, is used for routine immunization. H...
Detailed Description
Wild Polio Virus 1 (WPV1) is the only responsible virus for wild polio cases across the globe. The world has successfully eradicated wild poliovirus (PV) 2 and 3. Poliomyelitis eradication has entered...
Eligibility Criteria
Inclusion
- born healthy with birth weight 2.0 kg or more, with immediate cry.
- Parents resident of the study areas Not planning to travel away during entire the study period (birth-154 days; birth - 22 weeks) for 3 months at the time of enrolment
- Parent/guardian provides informed consent
Exclusion
- Refusal of blood testing and cord blood testing
- Receipt of OPV after birth before eligibility screen
- Newborns with certain medical conditions i.e., syndromic infants, neonate with petechial or purpura (contraindication of intramuscular injections)
- A confirmed diagnosis of immunodeficiency disorder in a blood relative will render the newborn ineligible for the study.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
560 Patients enrolled
Trial Details
Trial ID
NCT04504539
Start Date
August 1 2020
End Date
December 1 2021
Last Update
August 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aga Khan University
Karachi, Pakistan, 74800